Deciphering the mechanisms of environmentally mediated Alectinib resistance in ALK plus NSCLC

被引：0
|
作者：
Kumar, Pragya
Turati, Virginia
Marusyk, Andriy
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 10期
关键词：
D O I：
10.1158/1538-7445.EVODYN22-B032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B032
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Alectinib superior to chemotherapy in advanced ALK plus NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (06): : E285 - E285
  • [2] Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
    Doebele, Robert Charles
    Aisner, Dara L.
    Le, Anh T.
    Berge, Eamon M.
    Pilling, Amanda B.
    Kutateladze, Tatiana G.
    Weickhardt, Andrew James
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] KRAS mutation as a mechanism of resistance to Alectinib in ALK rearranged NSCLC
    Batra, Ullas
    Nathany, Shrinidhi
    Sharma, Mansi
    Jain, Parveen
    Bansal, Abhishek
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2021, 3
  • [4] Intrinsic ALK-TKI Resistance Due to MetCoamplification in ALK plus NSCLC, Effectively Treated by Alectinib-crizotinib Combination
    Urbanska, E. M.
    Melchior, L. C.
    Sorensen, J. B.
    Santoni-Rugiu, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S645 - S646
  • [5] Targeted adjuvant: First Data on Alectinib in Patients with operable ALK plus NSCLC
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
  • [6] Intrinsic and acquired resistance mechanisms of alectinib in ALK rearranged cells
    Hibino, Yukiko
    Takaaki, Sasaki
    Minami, Yoshinori
    Janne, Pasi A.
    Ohsaki, Yoshinobu
    CANCER RESEARCH, 2014, 74 (19)
  • [7] A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants
    He, Muyang
    Li, Weikang
    Zheng, Qingchuan
    Zhang, Hongxing
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (07) : 5332 - 5342
  • [8] The efficacy and safety of alectinib in the treatment of ALK plus NSCLC: a systematic review and meta-analysis
    Fan, Junsheng
    Xia, Zengfei
    Zhang, Xiaoli
    Chen, Yuqing
    Qian, Ruolan
    Liu, Sihan
    You, Danming
    Zhang, Jian
    Luo, Peng
    ONCOTARGETS AND THERAPY, 2018, 11 : 1105 - 1115
  • [9] ESMO 2023 Adjuvant alectinib in operable ALK plus NSCLC, precision medicine in CUP syndrome
    Freyer, Martina
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (1-2)
  • [10] Alectinib: A Review in Advanced, ALK-Positive NSCLC
    Paik, Julia
    Dhillon, Sohita
    DRUGS, 2018, 78 (12) : 1247 - 1257
12345